论文部分内容阅读
目的评价马来酸桂哌齐特治疗肾绞痛的临床疗效及安全性。方法将76例肾绞痛患者随机分成对照组36例和试验组40例。对照组予以肌内注射氯诺昔康8 mg+黄体酮40 mg,qd;试验组在对照组的基础上,加用静脉滴注马来酸桂哌齐特320 mg+10%葡萄糖注射液500 m L,糖尿病患者改为0.9%氯化钠500 m L,qd。观察患者6 h内疼痛缓解程度、是否复发和不良反应发生率。结果试验组有效率和显效率分别为100.00%和92.50%显著高于对照组88.89%和69.40%(P<0.05)。6 h内试验组肾绞痛再发率为0显著低于对照组再发率13.89%(P<0.05)。2组均未见明显的药物相关性不良反应。结论马来酸桂哌齐特能够明显缓解肾绞痛,降低再发率,且无明显不良反应,值得临床推荐。
Objective To evaluate the clinical efficacy and safety of Cinepazide maleate in the treatment of renal colic. Methods 76 patients with renal colic were randomly divided into control group (36 cases) and experimental group (40 cases). The control group was given intramuscular injection of lornoxicam 8 mg + progesterone 40 mg, qd; on the basis of the control group, the experimental group was treated with intravenous infusion of cinepazide maleate 320 mg + 10% glucose 500 m L, diabetic patients to 0.9% sodium chloride 500 m L, qd. Patients were observed within 6 h of pain relief, whether the recurrence and adverse reactions. Results The effective rate and effective rate in the experimental group were 100.00% and 92.50%, respectively, which were significantly higher than those in the control group (88.89% and 69.40%, P <0.05). Within 6 h, the relapse rate of renal colic in the experimental group was significantly lower than that in the control group (13.89%, P <0.05). No obvious drug-related adverse reactions were observed in both groups. Conclusion Cinepazide maleate can relieve renal colic significantly, reduce the recurrence rate, and no obvious adverse reactions, it is clinically recommended.